Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Dinslaken – page 125

1 725 clinical trials in Dinslaken, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Dinslaken at a glance
1 725
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 725 trials in Dinslaken

Open in trial search

Study on the Effects of Fordadistrogene Movaparvovec for Patients with Duchenne Muscular Dystrophy

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Eculizumab
  • Sponsor:Pfizer Inc.

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Breast cancer

Not recruiting

Study on Alpelisib and Fulvestrant for Men and Postmenopausal Women with Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA Mutation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Rheumatoid arthritis

Not recruiting

Study on the Long-Term Safety and Effectiveness of Filgotinib for Patients with Rheumatoid Arthritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Filgotinib
  • Sponsor:Alfasigma S.p.A.

Study on the Safety and Effectiveness of Diamyd and Colecalciferol for Adolescents and Adults with Recently Diagnosed Type 1 Diabetes

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Colecalciferol
  • Sponsor:Diamyd Medical AB

Psoriatic arthropathy

Not recruiting

Study on Long-Term Safety and Effectiveness of Bimekizumab for Adults with Active Psoriatic Arthritis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Study on Caplacizumab and Immunosuppressive Therapy for Adults with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Caplacizumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on the Long-Term Safety of Seladelpar for Patients with Primary Biliary Cholangitis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Seladelpar
  • Sponsor:Gilead Sciences Inc.

Neoplasm

Not recruiting

Study on the Effectiveness of Inavolisib, Atezolizumab, and Entrectinib in Patients with Advanced or Metastatic Solid Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:F. Hoffmann-La Roche AG

Study of Ifinatamab Deruxtecan for Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ifinatamab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Study of ianalumab versus placebo in adults with warm autoimmune hemolytic anemia who failed previous treatment

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Danazol
  • Sponsor:Novartis Pharma AG

Study on Durvalumab and Tremelimumab for Patients with Advanced Liver Cancer Not Treatable by Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.